Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuron Ltd Declaration of Voting Results & Voting Rights Announcements 2014

May 26, 2014

35121_rns_2014-05-26_510b212a-558b-4640-b625-00b0046002c9.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in viewer

Opens in your device viewer

==> picture [209 x 45] intentionally omitted <==

IMMURON LIMITED

(ASX: IMC)

Results of General Meeting

Tuesday, 27[th] May 2014

The Company wishes to advise that all resolutions were unanimously carried on show of hands.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the General Meeting held today.

Resolution Resolution For Against Abstain Proxy'sDiscretion* Total ValidProxiesReceived
1 Ratification of Prior Issue of UnlistedOptions 1,435,833,857 64,958,931 325,415 71,149,744 1,571,942,532
2 Approve the Issue of Shares to GrandlodgePtyltd or its Nominee 919,873,081 55,040,599 526,204,523 71,149,744 1,046,063,424
3 Approve the Issue of Unlisted Options toReza Moussakhani or his Nominee 1,445,736,189 55,040,599 291,415 71,199,744 1,571,976,532
4 Adoption of New Constitution 1,259,045,749 54,847,259 187,175,195 71,199,744 1,385,092,752
  • The Chairman voted undirected proxies in his control in favour of all resolutions.

For and on behalf of the Board;

==> picture [97 x 37] intentionally omitted <==

Peter Vaughan Company Secretary

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron’s technology platform products all have a very high safety profile. The company’s current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers’ diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735